Illumina, Inc. (NASDAQ:ILMN) has earned a consensus rating of “Hold” from the twenty-four ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $175.02.

ILMN has been the topic of a number of analyst reports. Morgan Stanley reiterated an “underweight” rating and issued a $115.00 price target (up previously from $108.00) on shares of Illumina in a research report on Monday, May 15th. Vetr upgraded Illumina from a “buy” rating to a “strong-buy” rating and set a $196.89 price target on the stock in a research report on Wednesday, May 17th. BidaskClub upgraded Illumina from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Finally, Barclays PLC reiterated a “hold” rating and issued a $150.00 price target on shares of Illumina in a research report on Wednesday, July 19th.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/08/30/illumina-inc-ilmn-given-consensus-rating-of-hold-by-analysts.html.

Illumina (ILMN) traded up 1.94% during mid-day trading on Wednesday, reaching $199.74. The company’s stock had a trading volume of 798,549 shares. Illumina has a 12 month low of $119.37 and a 12 month high of $200.00. The stock’s 50 day moving average is $183.92 and its 200 day moving average is $176.00. The company has a market cap of $29.16 billion, a price-to-earnings ratio of 40.08 and a beta of 0.83.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm had revenue of $662 million for the quarter, compared to analyst estimates of $642.38 million. During the same quarter in the previous year, the company posted $0.86 EPS. The business’s revenue was up 10.3% on a year-over-year basis. Equities research analysts predict that Illumina will post $3.65 EPS for the current year.

In other news, SVP Charles Dadswell sold 145 shares of the stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $184.75, for a total value of $26,788.75. Following the completion of the sale, the senior vice president now directly owns 10,791 shares of the company’s stock, valued at $1,993,637.25. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $194.73, for a total value of $3,894,600.00. Following the completion of the sale, the director now directly owns 539,176 shares of the company’s stock, valued at $104,993,742.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 138,185 shares of company stock worth $25,063,480. 1.60% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of ILMN. First Citizens Bank & Trust Co. increased its stake in shares of Illumina by 0.4% in the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock valued at $536,000 after buying an additional 12 shares during the period. Patten Group Inc. increased its stake in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares during the period. Puzo Michael J increased its stake in shares of Illumina by 0.4% in the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock valued at $1,032,000 after buying an additional 25 shares during the period. Flagship Harbor Advisors LLC increased its stake in shares of Illumina by 1.7% in the second quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock valued at $345,000 after buying an additional 35 shares during the period. Finally, Eqis Capital Management Inc. increased its stake in shares of Illumina by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences company’s stock valued at $1,200,000 after buying an additional 38 shares during the period. 93.32% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.